SCHEMBL1405516

SCHEMBL1405516

C1=CCN2CCCCC2=C1

nearest known ligand 0.30

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3904361 0.98
SCHEMBL5130701 0.98 USP2 (0.32) ACHE
SCHEMBL19004321 0.84
SCHEMBL31696522 0.74 ALDH1A1 (0.33)
SCHEMBL17934702 0.74
SCHEMBL31280721 0.71 PARP1 (0.54)
SCHEMBL3413900 0.69
SCHEMBL10482676 0.68 ALDH1A1 (0.37)
SCHEMBL13176438 0.67 MAOA (0.30)
SCHEMBL2362137 0.67 ALDH1A1 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240217990-A1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES, INC. 2024-07-04 US disclosed
US-20240217990-A1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES, INC. 2024-07-04 US disclosed
US-20220257781-A1 POLYMER CONJUGATE BONDED TO TERTIARY AMINE COMPOUND OR IMINE COMPOUND AND PRODUCTION METHOD THEREFOR SEIKAGAKU CORPORATION (JP) 2022-08-18 US disclosed
CN-110072864-B TDO2 inhibitors 基因泰克公司 2022-05-27 CN disclosed
US-20220040318-A1 PRIMARY AMINE COMPOUND OR SECONDARY AMINE COMPOUND-ACIDIC POLYSACCHARIDE CONJUGATE AND PRODUCTION METHOD THEREFOR SEIKAGAKU CORPORATION (JP) 2022-02-10 US disclosed
US-20200138964-A1 TERTIARY AMINE COMPOUND OR IMINE COMPOUND-POLYMER CONJUGATE AND PRODUCTION METHOD THEREFOR SEIKAGAKU CORPORATION (JP) 2020-05-07 US disclosed
EP-2004713-B1 LOADED LATEX OPTICAL MOLECULAR IMAGING PROBES CARESTREAM HEALTH INC (US) 2011-03-09 EP disclosed
WO-2010132908-A1 METHOD FOR THE QUALITATIVE AND/OR QUANTITATIVE ANALYSIS OF TUMOUR CELLS ONKOTEC GMBH (AT) 2010-11-25 WO disclosed
EP-2188634-A1 FLUORESCENCE RESONANCE ENERGY TRANSFER DETECTION WITH NANOPARTICLES Carestream Health, Inc. (US) 2010-05-26 EP disclosed
WO-2010016858-A2 MOLECULAR IMAGING PROBES CARESTREAM HEALTH, INC. (US) 2010-02-11 WO disclosed
WO-2009032236-A1 FLUORESCENCE RESONANCE ENERGY TRANSFER DETECTION WITH NANOPARTICLES CARESTREAM HEALTH, INC. (US) 2009-03-12 WO disclosed
US-20060128823-A1 Radiation curable inkjet recording ink, and method of producing planographic printing plate using same, and ink composition, inkjet recording method, printed material, method of producing a planographic printing plate, and planographic printing plate FUJI PHOTO FILM CO., LTD. 2006-06-15 US disclosed
EP-1657286-A2 Radiation curable ink jet ink, comprising a polymerisation initiation sensitising dye FUJI PHOTO FILM CO., LTD. (JP) 2006-05-17 EP disclosed
EP-0596098-A1 FLUORESCENT MICROPARTICLES WITH CONTROLLABLE ENHANCED STOKES SHIFT MOLECULAR PROBES, INC. (US) 1994-05-11 EP disclosed
WO-1993023492-A1 FLUORESCENT MICROPARTICLES WITH CONTROLLABLE ENHANCED STOKES SHIFT MOLECULAR PROBES, INC. (US) 1993-11-25 WO disclosed
US-4971958-A CALCIUM METABOLISM BOEHRINGER MANNHEIM GMBH (DE) 1990-11-20 US disclosed
EP-0147805-B1 SPIRO-LINKED PYRROLIDINE-2,5-DIONES AND PROCESS FOR THEIR PREPARATION KYORIN PHARMACEUTICAL CO., LTD. (JP) 1990-10-10 EP disclosed
US-4593092-A Spiro-linked pyrrolidin-2,5-dione KYORIN PHARMACEUTICAL CO., LTD. (JP) 1986-06-03 US disclosed
EP-0147805-A2 Spiro-linked pyrrolidine-2,5-diones and process for their preparation KYORIN PHARMACEUTICAL CO., LTD. (JP) 1985-07-10 EP disclosed
US-3948923-A HYPOTENSIVE, VASODILATION BAYER AKTIENGESELLSCHAFT (DT) 1976-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220257781-A1 POLYMER CONJUGATE BONDED TO TERTIARY AMINE COMPOUND OR IMINE COMPOUND AND PRODUCTION METHOD THEREFOR ODC1, DOHH, SMYD2 ACHE 3020/4885
US-20240217990-A1 THIENOPYRROLE COMPOUNDS SSB, TPMT, LCP2 ACHE 4058/4885
US-20200138964-A1 TERTIARY AMINE COMPOUND OR IMINE COMPOUND-POLYMER CONJUGATE AND PRODUCTION METHOD THEREFOR SOAT1, SLC7A1, ODC1 ACHE 2260/4885
US-20220040318-A1 PRIMARY AMINE COMPOUND OR SECONDARY AMINE COMPOUND-ACIDIC POLYSACCHARIDE CONJUGATE AND PRODUCTION METHOD THEREFOR ALG1, NGLY1, SAT1 ACHE 1778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.